{
  "symbol": "INCY",
  "name": "Incyte",
  "sector": "Health Care",
  "industry": "Biotechnology",
  "date_added": "2017-02-28",
  "headquarters": "Wilmington, Delaware",
  "founded": "1991",
  "market_cap": 13215.991808,
  "pe_ratio": 341.375,
  "forward_pe": 11.119707,
  "eps": 0.2,
  "revenue": 4413.225984,
  "profit_margin": 0.00482,
  "debt_to_equity": 1.176,
  "return_on_equity": 0.0046900003,
  "dividend_yield": null,
  "current_price": 68.2750015258789,
  "year_high": 83.94999694824219,
  "year_low": 53.560001373291016,
  "price_change_1d": 0.894049613276387,
  "price_change_1w": -0.6620133985615267,
  "price_change_1m": 1.5392678390715104,
  "description": "Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia an",
  "website": "https://www.incyte.com",
  "employees": 2617,
  "exchange": "NMS",
  "currency": "USD",
  "analyst_target_price": 75.14522,
  "recommendation": 2.33333,
  "number_of_analysts": 23,
  "earnings_history": [],
  "analyst_data": {
    "target_high": 107.0,
    "target_low": 52.0,
    "target_mean": 75.14522,
    "target_median": 72.34
  },
  "last_updated": "2025-07-09T11:23:32.934217",
  "data_quality": {
    "has_financial_data": true,
    "has_earnings_data": false,
    "has_analyst_data": true,
    "completeness_score": 0.6666666666666666
  }
}